CN107468725A - A kind of Chinese medicine composition and its application with function of reducing blood sugar and the parenteral solution being made from it - Google Patents

A kind of Chinese medicine composition and its application with function of reducing blood sugar and the parenteral solution being made from it Download PDF

Info

Publication number
CN107468725A
CN107468725A CN201710701144.3A CN201710701144A CN107468725A CN 107468725 A CN107468725 A CN 107468725A CN 201710701144 A CN201710701144 A CN 201710701144A CN 107468725 A CN107468725 A CN 107468725A
Authority
CN
China
Prior art keywords
ginkgo leaf
ginkalide
sequoyitol
alcohol
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710701144.3A
Other languages
Chinese (zh)
Inventor
王�锋
杨满辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lang Group Jiangxi Medicine Co Ltd
Original Assignee
Lang Group Jiangxi Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lang Group Jiangxi Medicine Co Ltd filed Critical Lang Group Jiangxi Medicine Co Ltd
Priority to CN201710701144.3A priority Critical patent/CN107468725A/en
Publication of CN107468725A publication Critical patent/CN107468725A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/06—Products with modified nutritive value, e.g. with modified starch content
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/36—Vegetable material
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Abstract

Chinese medicine composition provided by the invention, total flavonoids without hypoglycemic effect, Ginkgolide A. B. C are engaged by pine camphor, sequoyitol, total flavonoids, Ginkgolide A. B. C including specified weight part with pine camphor and sequoyitol, improve the hypoglycemic effect of pine camphor and sequoyitol so that the composition of the application has significant hypoglycemic effect.

Description

A kind of Chinese medicine composition and its application with function of reducing blood sugar and the note being made from it Penetrate liquid
Technical field
The present invention relates to field of Chinese medicinal composition, and in particular to a kind of Chinese medicine composition with function of reducing blood sugar, and the group The preparation method and application of compound.
Background technology
Sugar in blood of human body is referred to as blood glucose, mostlys come from cereal, vegetables and fruits of human body intake etc., and above-mentioned food passes through Digestive system is converted into monose (such as glucose) and enters blood, is transported to systemic cell, the source as energy.If for the moment Do not consume, be then converted into glycogen storage in liver and muscle, liver can store up sugar 70~120 grams, account for liver weight 6~ 10%.The glycogen that cell can store is limited, if sugared part of intake is excessive, unnecessary sugar is changed into fat.Normally Fasting plasma glucose concentration is 80~120 milligrams of % to people in the morning, and more than 130 milligrams % of fasting plasma glucose concentration are referred to as hyperglycaemia, if More than 160~180 milligrams % of blood sugar concentration, with regard to some glucose with urine ejection, here it is glycosuria.
Too fast urban life rhythm, make people's mood or spiritual pressure overweight, fluctuating for mood is too big, meeting Some organ dysfunctions in human body are prevented to cause vivo environment disorderly from normally playing, make blood glucose rise.In addition life bar The raising of part, hyperphagia sweet food or Sugared beverages, make the sugar content in human body apparently higher than arm's length standard, while can also shape Fat increase, causes blood glucose height into blood.In addition, normal diet is upset and disturbed to long-term alcohol, so as to suppress gluconeogenesis Effect, the hypoglycemic composition effect such as insulin is reduced, will also result in blood glucose rise.Above-mentioned various reasons cause hyperglycaemia to present To the trend for the development that becomes younger, PATIENT POPULATION increasingly increases and speedup is surprising, and hyperglycaemia, hypertension and hyperlipemia can cause Diabetes, and easily other many complication of induction such as atherosclerosis, coronary heart disease, have been increasingly becoming harm human health The hidden danger of most serious.According to statistics, at home in the ten big causes of death, the death toll related to " three high diseases " accounts for total death toll 27%.
Sequoyitol (Sequoyitol, CAS:523-92-2) alias sequoyitol, the entitled 5-O-methyl- of its chemistry Myoinositol (or 5-O-methyl-myoinositol), molecular formula C7H14O6, molecular weight 194.18, chemical structural formula is such as Under：
Sequoyitol is initially obtained by being extracted in Chinese yew, because growth of taxol is slower, for pharmacy and does not meet economy Efficiency, therefore there are many people to try to obtain sequoyitol from other plant, now research finds that it is also present in other gymnosperms In the plant such as (for example, ginkgo), pulse family Trifolium, Aristolochiaceae.Sequoyitol is the methyl-derivatives of inositol, and early stage studies table Bright sequoyitol can significantly reduce diabetes model hyperglycaemia, suppression hepatic glycogenolytic and glucose absorption, reduce blood fat, improve certainly It is metabolized by base and is protected beta Cell of islet.
Pine camphor (D-pinitol CAS:10284-63-6), molecular formula C7H14O6, molecular weight 194.18, chemical constitution Formula is as follows：
D- pine camphors are the crystallization of white granular, are easily soluble in water, odorless, the micro- sweet tea of taste, are insoluble in methanol, ethanol, no Chloroform, ether, acetone and other organic solvent are dissolved in, at present for the preparation of D- pine camphors, is mainly provided using chemical synthesis and from natural Two methods are extracted in source.It has extensive plant origin in oneself boundary, and Recent study finds that it has a variety of physiology Activity, such as insulin-sensitizing effect, hypoglycemic, antitumor, immunological regulation, anti-inflammatory antioedematous.
Although sequoyitol and pine camphor are respectively provided with the effect of hypoglycemic, the effect of single component is not notable, and both are mixed The hypoglycemic effect for closing the composition formed is not also significantly improved, and it can be compounded with which kind of bulk drug to improve its drop The effect of blood glucose, due to its different final drug effect of Chinese medicine composition compatibility and differ, even if the raw material phase interworking of identical effect Close, can not be completely secured and not produce antagonism and blood sugar reducing function is weakened or is produced other serious side effects, so that Screening using pine camphor and sequoyitol as the composition with notable hypoglycemic effect of bulk drug becomes abnormal difficult.
The content of the invention
Therefore, it is an object of the invention to provide a kind of Chinese traditional medicine composition with blood sugar reducing function comprising sequoyitol and pine camphor Thing, it is intended to more in-depth study is carried out to sequoyitol and pine camphor, expands its application, further, the application also provides Parenteral solution comprising the Chinese medicine composition and preparation method thereof.
Therefore, the technical scheme that the application takes is,
A kind of Chinese medicine composition with effect of lowering blood sugar, include the component of following parts by weight, pine camphor 16-24 parts, Chinese larch Alcohol 2-4 parts, total flavonoids 7-15 parts, ginkalide A 0.7-2 parts, ginkolide B 0.3-1 parts, ginkalide C 0.4-1 Part.
In the above-mentioned Chinese medicine composition with effect of lowering blood sugar, the pine camphor or sequoyitol are made by being extracted in ginkgo leaf.
In the above-mentioned Chinese medicine composition with effect of lowering blood sugar, the total flavonoids, ginkalide A, ginkolide B and Ginkalide C is made by being extracted in ginkgo leaf.
A kind of preparation for including any of the above-described described composition, the composition adds customary adjuvant, according to conventional work Skill, clinically acceptable tablet, capsule, powder, mixture, pill, granule, oral liquid, syrup, paste, punching is made Agent, vina, injection, beverage, biscuit, candy, cake food or instant food.
The preparation of any of the above-described described composition or described composition is in the medicine with hypoglycemic effect is prepared Application.
A kind of method for preparing the parenteral solution comprising any of the above-described composition, including by sequoyitol, flavonol glycosides, silver Apricot lactone A, ginkolide B, ginkalide C and water, auxiliary material are mixed and made into sterile solution, wherein the sequoyitol is described sterile Content in solution is 0.1-3mg/ml.
A kind of method for preparing the injection comprising any of the above-described composition, including,
(1) after ginkgo leaf crushes, 85-90% alcohol refluxs are added to extract 3 or 4 times, each reflux extracting time 1-1.5 is small When, the amount of alcohol of addition is 6-9 times of ginkgo leaf weight, and filtering concentrates the filtrate to 0.2 times of ginkgo leaf weight, and refrigeration 48 is small When；
(2) oil slick is scraped off, takes subnatant；
(3) 0.5 times of ginkgo leaf weight is injected water to, is refrigerated 48 hours, filtering, filtrate decompression is concentrated into ginkgo leaf 0.2 times of weight, puts to room temperature, adds 90%-95% ethanol, alcohol content is carried out the solution after alcohol precipitation successively cold to 80% Hide, filter and concentrate, repeat 2 times；
(4) filtrate after concentrating injects water to 0.2 times of ginkgo leaf weight, successively by resin cation and it is cloudy from Subtree fat progress adsorption treatment, wherein resin cation dosage are 2.5-3.5 times of ginkgo leaf and measured that resin anion (R.A.) dosage is silver 0.8-1.2 times of apricot leaf is measured；
(5) decoction after adsorption treatment adds auxiliary material and water, is made sterile solution, and sequoyitol contains in the sterile solution Measure as 0.1-3mg/ml.
In the above-mentioned method for preparing injection, the resin cation dosage is 3 times of ginkgo leaf and measured, the anion tree Fat dosage is 1 times of amount of ginkgo leaf.
In the above-mentioned method for preparing injection, the pH value of the sterile solution is 4.0-7.0.
A kind of any of the above-described methods described prepares the parenteral solution to be formed.
Technical solution of the present invention, have the following advantages that：
1st, Chinese medicine composition provided by the invention, including the pine camphor of specified weight part, sequoyitol, total flavonoids, ginkgo Total flavonoids without hypoglycemic effect, Ginkgolide A. B. C are engaged by lactone A, B, C with pine camphor and sequoyitol, are carried The high hypoglycemic effect of pine camphor and sequoyitol so that the composition of the application has significant hypoglycemic effect.
2nd, the present invention is extracted from ginkgo leaf using specific method and obtained containing sequoyitol, ginkalide A, ginkgolides B, the decoction of ginkalide C and total flavonoids, and the sterile solution that the content that sequoyitol is finally made is 0.1-3mg/L, from And the effect of hypoglycemic is made it have, the use range of ginkgo leaf is expanded, improves its medical value.
Embodiment
Pine camphor, sequoyitol, ginkalide A, ginkolide B, ginkalide C and total flavonoids used herein can To be commercially available or extract and obtain from plant by existing process, for purposes of illustration only, following examples of the present invention In, pine camphor, sequoyitol, ginkalide A, ginkolide B, ginkalide C and total flavonoids are commercially available product.
Embodiment 1
There is the present embodiment the raw material of the composition of hypoglycemic effect to form：Pine camphor is 16g, sequoyitol 4g, total Huang Keto-alcohol glycosides is 7g, ginkalide A 2g, ginkolide B are 0.3g and ginkalide C is 1g.
Above-mentioned sequoyitol, flavonol glycosides, ginkalide A, ginkolide B, ginkalide C and water, auxiliary material are mixed PH value is 7.0 sterile solution, wherein content of the sequoyitol in the sterile solution is 0.1mg/ml.
Embodiment 2
There is the present embodiment the raw material of the composition of hypoglycemic effect to form：Pine camphor is 24g, sequoyitol 2g, total Huang Keto-alcohol glycosides is 15g, ginkalide A 0.7g, ginkolide B are 1g and ginkalide C is 0.4g.
Above-mentioned sequoyitol, flavonol glycosides, ginkalide A, ginkolide B, ginkalide C and water, auxiliary material are mixed PH value is 6.0 sterile solution, wherein content of the sequoyitol in the sterile solution is 1.5mg/ml.
Embodiment 3
There is the present embodiment the raw material of the composition of hypoglycemic effect to form：Pine camphor is 18g, sequoyitol 3g, total Huang Keto-alcohol glycosides is 10g, ginkalide A 0.8g, ginkolide B are 0.4g and ginkalide C is 0.5g.
Above-mentioned sequoyitol, flavonol glycosides, ginkalide A, ginkolide B, ginkalide C and water, auxiliary material are mixed PH value is 7.0 sterile solution, wherein content of the sequoyitol in the sterile solution is 1mg/ml.
Embodiment 4
There is the present embodiment the raw material of the composition of hypoglycemic effect to form：Pine camphor is 20g, sequoyitol 4g, total Huang Keto-alcohol glycosides is 12g, ginkalide A 1.5g, ginkolide B are 0.6g and ginkalide C is 0.8g.
Above-mentioned sequoyitol, flavonol glycosides, ginkalide A, ginkolide B, ginkalide C and water, auxiliary material are mixed PH value is 4.0 sterile solution, wherein content of the sequoyitol in the sterile solution is 2mg/ml.
Embodiment 5
There is the present embodiment the raw material of the composition of hypoglycemic effect to form：Pine camphor is 22g, sequoyitol 2g, total Huang Keto-alcohol glycosides is 14g, ginkalide A 1.2g, ginkolide B are 0.8g and ginkalide C is 0.9g.
Above-mentioned sequoyitol, flavonol glycosides, ginkalide A, ginkolide B, ginkalide C and water, auxiliary material are mixed PH value is 5.0 sterile solution, wherein content of the sequoyitol in the sterile solution is 3mg/ml.
Embodiment 6
(1) after ginkgo leaf crushes, 85% alcohol reflux is added to extract 4 times, each reflux extracting time 1h, the amount of alcohol of addition For 9 times of ginkgo leaf weight, filtering concentrates the filtrate to 0.2 times of ginkgo leaf weight, refrigerates 48 hours；
(2) oil slick is scraped off, takes subnatant.
(3) 0.5 times of ginkgo leaf weight is injected water to, is refrigerated 48 hours, filtering.Filtrate decompression is concentrated into ginkgo leaf 0.2 times of weight, puts to room temperature, adds 95% ethanol, alcohol content is refrigerated the solution after alcohol precipitation successively, mistake to 80% Filter and concentration, repeat 2 times.
(4) filtrate after concentrating injects water to 0.2 times of ginkgo leaf weight, successively by resin cation and it is cloudy from Subtree fat carries out adsorption treatment.Wherein positive resin dosage is 3 times of amounts of ginkgo leaf medicinal material, and resin anion (R.A.) dosage is ginkgo leaf medicine 1 times of amount of material.
(5) decoction after adsorption treatment adds the water of 4 times of auxiliary material and quality of liquid medicine, be made pH value be 6.0 it is sterile water-soluble Liquid.
Detected using high performance liquid chromatography, in above-mentioned aseptic aqueous solution, its pine camphor 3.6mg/ml, sequoyitol 1mg/ Ml, total flavonoids 2mg/ml, ginkalide A 0.31mg/mL, ginkolide B 0.11mg/ml, ginkalide C are 0.08mg/ml。
Embodiment 7
(1) after ginkgo leaf crushes, 90% alcohol reflux is added to extract 3 times, each reflux extracting time 1.5 hours, addition Amount of alcohol is 6 times of ginkgo leaf weight, and filtering concentrates the filtrate to 0.2 times of ginkgo leaf weight, refrigerates 48 hours；
(2) oil slick is scraped off, takes subnatant.
(3) 0.5 times of ginkgo leaf weight is injected water to, is refrigerated 48 hours, filtering.Filtrate decompression is concentrated into ginkgo leaf 0.2 times of weight, puts to room temperature, adds 90% ethanol, alcohol content is refrigerated the solution after alcohol precipitation successively, mistake to 80% Filter and concentration, repeat 2 times.
(4) filtrate after concentrating injects water to 0.2 times of ginkgo leaf weight, successively by resin cation and it is cloudy from Subtree fat carries out adsorption treatment.Wherein positive resin dosage is 2.5 times of amounts of ginkgo leaf medicinal material, and resin anion (R.A.) dosage is ginkgo leaf 0.8 times of amount of medicinal material.
(5) decoction after adsorption treatment adds the water of 4 times of auxiliary material and quality of liquid medicine, be made pH value be 4.0 it is sterile water-soluble Liquid.
Detected using high performance liquid chromatography, in above-mentioned aseptic aqueous solution, its pine camphor 4mg/ml, sequoyitol 0.8mg/ Ml, flavonol glycosides 1.8mg/ml, ginkalide A 0.26mg/mL, ginkolide B 0.08mg/ml, ginkalide C are 0.11mg/ml。
Embodiment 8
(1) after ginkgo leaf crushes, 87% alcohol reflux is added to extract 3 times, each reflux extracting time 70min, the second of addition Alcohol amount is 7 times of ginkgo leaf weight, and filtering concentrates the filtrate to 0.2 times of ginkgo leaf weight, refrigerates 48 hours；
(2) oil slick is scraped off, takes subnatant.
(3) 0.5 times of ginkgo leaf weight is injected water to, is refrigerated 48 hours, filtering.Filtrate decompression is concentrated into ginkgo leaf 0.2 times of weight, puts to room temperature, adds 95% ethanol, alcohol content is refrigerated the solution after alcohol precipitation successively, mistake to 80% Filter and concentration, repeat 2 times.
(4) filtrate after concentrating injects water to 0.2 times of ginkgo leaf weight, successively by resin cation and it is cloudy from Subtree fat carries out adsorption treatment.Wherein positive resin dosage is 3.5 times of amounts of ginkgo leaf medicinal material, and resin anion (R.A.) dosage is ginkgo leaf 1.2 times of amounts of medicinal material.
(5) decoction after adsorption treatment adds the water of 1 times of auxiliary material and quality of liquid medicine, be made pH value be 7.0 it is sterile water-soluble Liquid.
Detected using high performance liquid chromatography, in above-mentioned aseptic aqueous solution, its pine camphor 18mg/ml, sequoyitol 2mg/ml, Total flavonoids 9mg/ml, ginkalide A 0.8mg/mL, ginkolide B 0.6mg/ml, ginkalide C 0.6mg/ml.
Influence of the composition to blood glucose in the experimental example present invention
Given the test agent：Method according to embodiment 3 and embodiment 6 is made.
Experimental animal：Regular grade Wistar big white mouse 120, male, body weight (200 ± 10) g.By Hebei province experimental animal Center provides, credit number：SCXK (Ji) 2008-1-003.
Main agents and instrument
Alloxan (sigma companies), metformin hydrochloride tablet (Shanghai Shi Guibao pharmaceutical Co. Ltds of Sino-U.S.), glucose Kit (Nanjing Sen Beijia bio tech ltd) is determined, (the sharp centrifuge in Beijing epoch north is limited for high speed tabletop centrifuge Company), 0.9% physiological saline (Shiyao Yinhu Pharmaceutical Co., Ltd.), electronic balance (Harbin Zhong Hui weighing apparatus Co., Ltd).
Experimental method
The foundation of diabetes rat model
Healthy rat 120 is taken, adaptability feeds 1-2 days after steady, and it is one group of Normal group to take 10 at random, its Remaining after 110 Rat Fast 18h, glycosuria is caused with (now with the current) intraperitoneal injections of alloxan normal saline solution 180mg/kg Disease model.50% glucose solution of gavage 4ml/ after injection 4h.Fasting 4h tail vein bloods after 6 days, new separation serum is found, is surveyed Determine glucose content, blood glucose value is that 15-35mmol/L is set to diabetes model success animal.
Composition causes the experiment of diabetes rat fasting blood-glucose to alloxan
Randomly select 60 rats and be divided into six groups, every group 10.Two group model control groups, three groups of metformin hydrochloride tablets Group, four groups of composition (ZHW) groups.One group and two groups of gavage distilled waters, the aqueous solution of three groups of gavage metformin hydrochloride tablets (10mg/ml), aseptic aqueous solution prepared by four groups of gavage embodiments 3, aseptic aqueous solution prepared by five groups of gavage embodiments 6, six The aseptic aqueous solution (sequoyitol 1mg/ml, pine camphor 6mg/ml) of group gavage sequoyitol and pine camphor mixture, in seven groups of gavage ginkgoes (Ginkgolide A. B. C is respectively 0.31,0.11 and 0.08mg/ to the aseptic aqueous solution of ester A, B, C and total flavonoids mixture Ml, total flavonoids 2mg/ml).
Every group of gavage is isodose by test product 2.5ml.Tail vein blood after fasting 0h, 2h and 4h after administration, centrifuge Serum, determine glucose content.
Experimental result
Influence of the composition of table 4 to blood glucose
Note：Arithmetic mean number, s standard deviations, * * P ＜ 0.01 compared with mono- group of y, * * P ＜ 0.01 be administered after with two groups of ratios Compared with.
As shown in Table 4, two to seven group rat fasting blood-glucose contents extremely notable rise (P ＜ 0.01) compared with one group.With two Group compares, and three groups, four groups and five groups blood-sugar contents have certain decline when 2h is administered, three groups, four groups and five groups blood when 4h is administered Sugared content significantly reduces (P ＜ 0.01).Further seven groups of effects with two groups substantially do not distinguish, show Ginkgolide A. B. C and Total flavonoids mixture does not have hypoglycemic effect, and six groups of blood-sugar contents have certain decline, but effect and three groups, four groups and five Group difference is obvious, though showing that pine camphor and Chinese larch alcohol mixture can be with hypoglycemic, effect is not notable.
Obviously, above-described embodiment is only intended to clearly illustrate example, and is not the restriction to embodiment.It is right For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of change or Change.There is no necessity and possibility to exhaust all the enbodiments.And the obvious change thus extended out or Among changing still in the protection domain of the invention.

Claims (10)

  1. A kind of 1. Chinese medicine composition with effect of lowering blood sugar, it is characterised in that include the component of following parts by weight,
    Pine camphor 16-24 parts
    Sequoyitol 2-4 parts；
    Total flavonoids 7-15 parts；
    Ginkalide A 0.7-2 parts；
    Ginkolide B 0.3-1 parts；
    Ginkalide C 0.4-1 parts.
  2. 2. the Chinese medicine composition according to claim 1 with effect of lowering blood sugar, it is characterised in that the pine camphor or Chinese larch Alcohol is made by being extracted in ginkgo leaf.
  3. 3. the Chinese medicine composition according to claim 1 or 2 with effect of lowering blood sugar, it is characterised in that the general flavone Alcohol glycosides, ginkalide A, ginkolide B and ginkalide C are made by being extracted in ginkgo leaf.
  4. A kind of 4. preparation of the composition including described in claim any one of 1-3, it is characterised in that
    The composition adds customary adjuvant, and according to common process, clinically acceptable tablet, capsule, powder, conjunction is made Agent, pill, granule, oral liquid, syrup, paste, electuary, vina, injection, beverage, biscuit, candy, cake food or Instant food.
  5. 5. the preparation of the composition described in claim any one of 1-3 or the composition described in claim 4 is being prepared with drop Application in the medicine of blood glucose effect.
  6. A kind of 6. method for preparing the parenteral solution comprising any compositions of claim 1-3, it is characterised in that including, by Sequoyitol, flavonol glycosides, ginkalide A, ginkolide B, ginkalide C and water, auxiliary material are mixed and made into sterile solution, wherein institute It is 0.1-3mg/ml to state content of the sequoyitol in the sterile solution.
  7. A kind of 7. method for preparing the injection comprising any compositions of claim 1-3, it is characterised in that including,
    (1) after ginkgo leaf crushes, add 85-90% alcohol refluxs to extract 3 or 4 times, each reflux extracting time 1-1.5 hours, add The amount of alcohol entered is 6-9 times of ginkgo leaf weight, and filtering concentrates the filtrate to 0.2 times of ginkgo leaf weight, refrigerates 48 hours；
    (2) oil slick is scraped off, takes subnatant；
    (3) 0.5 times of ginkgo leaf weight is injected water to, is refrigerated 48 hours, filtering, filtrate decompression is concentrated into ginkgo leaf weight 0.2 times, put to room temperature, add 90%-95% ethanol, alcohol content is refrigerated the solution after alcohol precipitation successively, mistake to 80% Filter and concentration, repeat 2 times；
    (4) filtrate after concentrating injects water to 0.2 times of ginkgo leaf weight, successively passes through resin cation and anion tree Fat progress adsorption treatment, wherein resin cation dosage are 2.5-3.5 times of ginkgo leaf and measured that resin anion (R.A.) dosage is ginkgo leaf 0.8-1.2 times measure；
    (5) decoction after adsorption treatment adds auxiliary material and water, is made sterile solution, and the content of sequoyitol is in the sterile solution 0.1-3mg/ml。
  8. 8. the method according to claim 7 for preparing injection, it is characterised in that the resin cation dosage is ginkgo 3 times of amounts of leaf, the resin anion (R.A.) dosage are 1 times of amount of ginkgo leaf.
  9. 9. according to any described methods for preparing parenteral solution of claim 6-8, it is characterised in that the pH value of the sterile solution For 4.0-7.0.
  10. 10. a kind of prepare the parenteral solution formed by any methods describeds of claim 6-9.
CN201710701144.3A 2017-08-16 2017-08-16 A kind of Chinese medicine composition and its application with function of reducing blood sugar and the parenteral solution being made from it Pending CN107468725A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710701144.3A CN107468725A (en) 2017-08-16 2017-08-16 A kind of Chinese medicine composition and its application with function of reducing blood sugar and the parenteral solution being made from it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710701144.3A CN107468725A (en) 2017-08-16 2017-08-16 A kind of Chinese medicine composition and its application with function of reducing blood sugar and the parenteral solution being made from it

Publications (1)

Publication Number Publication Date
CN107468725A true CN107468725A (en) 2017-12-15

Family

ID=60598856

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710701144.3A Pending CN107468725A (en) 2017-08-16 2017-08-16 A kind of Chinese medicine composition and its application with function of reducing blood sugar and the parenteral solution being made from it

Country Status (1)

Country Link
CN (1) CN107468725A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1706369A (en) * 2004-06-11 2005-12-14 广州威尔曼新药开发中心有限公司 Sequoyitol and sequoyitol extract for preventing and treating diabetes
CN1813782A (en) * 2005-12-02 2006-08-09 厦门国宇知识产权研究有限公司 Composition of ginkgo leaf extract and dipyridamole, medicine containing same and preparing method thereof
CN104605349A (en) * 2015-01-21 2015-05-13 天津科技大学 Health-care product containing D-pinitol and having blood glucose lowering function and function assessment method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1706369A (en) * 2004-06-11 2005-12-14 广州威尔曼新药开发中心有限公司 Sequoyitol and sequoyitol extract for preventing and treating diabetes
CN1813782A (en) * 2005-12-02 2006-08-09 厦门国宇知识产权研究有限公司 Composition of ginkgo leaf extract and dipyridamole, medicine containing same and preparing method thereof
CN104605349A (en) * 2015-01-21 2015-05-13 天津科技大学 Health-care product containing D-pinitol and having blood glucose lowering function and function assessment method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李明山: ""银杏叶提取物对胰岛素抵抗的影响"", 《中医药临床杂志》 *

Similar Documents

Publication Publication Date Title
JP2002524480A (en) Bioflavonoids as hypoglycemic agents
WO2004037018A1 (en) Composition for enhancing physical performance
WO2012034498A1 (en) Product of functional health food that enhances organ immunity
CN101033245B (en) Preparation method and application of pedunculoside
CN107441078A (en) A kind of pharmaceutical composition for treating diabetes and its production and use
CN103989677A (en) Use of demethyleneberberine in preparation of blood sugar-reduction drug
CN101766274B (en) Antioxidant functional food composition containing bamboo-leaves flavones
EP1562449A1 (en) Composition for enhancing physical performance
CN103919775A (en) Application of 9-demethylberberine in preparation of hpyerglycemic drug
CN102228539A (en) Rosa davurica total flavone extract, its extracting method and its medical use
EP1763360A2 (en) Extracts of passion fruit and uses thereof
JP2001508777A (en) Pine needle extract and its use
CN112274547A (en) A composition containing herba Silybi Mariani extract and fructose-1, 6-diphosphate, and its application in protecting liver, relieving hangover, and relieving fatigue
CN103655925B (en) A kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof
CN107468725A (en) A kind of Chinese medicine composition and its application with function of reducing blood sugar and the parenteral solution being made from it
CN107550923A (en) A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular disease and its application and the injection formed by its preparation
RU2408383C1 (en) Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions)
KR100314477B1 (en) Composition for improving lipid metabolism and decreasing bllod pressure which comprises jujube and citrus peel extracts
KR100595459B1 (en) Composition for inhibiting obesity
KR100940133B1 (en) Anti- diabetic composition containing crude extracts of Citrus aurantium and health assistant foods with valid component thereof
KR100296250B1 (en) Composition for improving lipid metabolism and lowering blood pressure containing jujube extract and tangerine pericarp extract
WO2009103164A1 (en) Anti-obesity compositions comprising orlistat and various natural products
CN104382956B (en) Golden ears or side handles of a utensil entity saponin extract and its production and use
CN109601804A (en) A kind of Sparassis crispa solid beverage
US7390517B2 (en) Extracts of passion fruit and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171215

RJ01 Rejection of invention patent application after publication